UNLIMITED TURBO LONG - NOVO-NORDISK B | Market Closed - Börse Stuttgart 04:11:59 2024-04-30 EDT | ||
| 20.41 EUR | -1.35% |
|
| Current month | -1.73% | ||
| 1 month | -1.73% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 20.41 | -1.35% | 0 |
| 24-04-29 | 20.69 | +2.12% | 0 |
| 24-04-26 | 20.26 | +0.40% | 0 |
| 24-04-25 | 20.18 | -2.79% | 0 |
| 24-04-24 | 20.76 | +1.42% | 0 |
Delayed Quote Börse Stuttgart
Last update April 30, 2024 at 04:11 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WKN | PP1XQ2 |
| ISIN | DE000PP1XQ29 |
| Date issued | 2017-11-14 |
| Strike | 116.6 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 1.32 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.58 € |
|---|---|
| Lowest since issue | 0.55 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
902.6
DKK
Average target price
904.2
DKK
Spread / Average Target
+0.18%
- Stock Market
- Certificates
- Certificat
